Trade, IP And Oncology Deals: What You Need To Know About China And JPM20
Executive Summary
China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.
You may also be interested in...
China Provides Patent Linkage In Latest Law Draft
In a significant development, China proposes to strengthen the protection of new drugs through not only patent linkage but also patent compensation in the latest draft of its revised Patent Law.
China Provides Patent Linkage In Latest Law Draft - Why Now?
In a significant development, China proposes to strengthen the protection of new drugs through not only patent linkage but also patent compensation in the latest draft of its revised Patent Law.
China Commits To Patent Linkage And Extensions In US Trade Deal
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.